Legis Daily

MODERN Labeling Act of 2020

USA116th CongressHR-5668| House 
| Updated: 11/18/2020
Doris O. Matsui

Doris O. Matsui

Democratic Representative

California

Cosponsors (2)
Brett Guthrie (Republican)Van Taylor (Republican)

Health, Education, Labor, and Pensions Committee, Health Subcommittee, Energy and Commerce Committee

  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted
Making Objective Drug Evidence Revisions for New Labeling Act of 2020 or the MODERN Labeling Act of 2020 This bill authorizes the Food and Drug Administration (FDA) to require updates to outdated labels for certain generic drugs if the updates will provide a public health benefit. Generally, the FDA may use this authority to update the label of a generic version of a brand-name drug that has been withdrawn from the market for reasons other than safety or effectiveness.

Bill Text Versions

View Text
4 versions available

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline
Jan 24, 2020
Introduced in House
Jan 24, 2020
Referred to the House Committee on Energy and Commerce.
Jan 25, 2020
Referred to the Subcommittee on Health.
Mar 11, 2020
Ordered to be Reported (Amended) by Voice Vote.
Mar 11, 2020
Subcommittee Consideration and Mark-up Session Held.
Jul 15, 2020
Ordered to be Reported (Amended) by Voice Vote.
Jul 15, 2020
Committee Consideration and Mark-up Session Held.
Nov 16, 2020
Placed on the Union Calendar, Calendar No. 471.
Nov 16, 2020
Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 116-573.
Nov 17, 2020
Mr. Pallone moved to suspend the rules and pass the bill, as amended.
Nov 17, 2020
Considered under suspension of the rules. (consideration: CR H5805-5807)
Nov 17, 2020
DEBATE - The House proceeded with forty minutes of debate on H.R. 5668.
Nov 17, 2020
Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.(text: CR H5805-5806)
Nov 17, 2020
On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H5805-5806)
Nov 17, 2020
Motion to reconsider laid on the table Agreed to without objection.
Nov 18, 2020
Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
  • January 24, 2020
    Introduced in House


  • January 24, 2020
    Referred to the House Committee on Energy and Commerce.


  • January 25, 2020
    Referred to the Subcommittee on Health.


  • March 11, 2020
    Ordered to be Reported (Amended) by Voice Vote.


  • March 11, 2020
    Subcommittee Consideration and Mark-up Session Held.


  • July 15, 2020
    Ordered to be Reported (Amended) by Voice Vote.


  • July 15, 2020
    Committee Consideration and Mark-up Session Held.


  • November 16, 2020
    Placed on the Union Calendar, Calendar No. 471.


  • November 16, 2020
    Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 116-573.


  • November 17, 2020
    Mr. Pallone moved to suspend the rules and pass the bill, as amended.


  • November 17, 2020
    Considered under suspension of the rules. (consideration: CR H5805-5807)


  • November 17, 2020
    DEBATE - The House proceeded with forty minutes of debate on H.R. 5668.


  • November 17, 2020
    Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.(text: CR H5805-5806)


  • November 17, 2020
    On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H5805-5806)


  • November 17, 2020
    Motion to reconsider laid on the table Agreed to without objection.


  • November 18, 2020
    Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Health

Related Bills

  • S 116-1897: A bill to establish a process for updating the labeling of certain drugs with outdated labeling.
  • S 116-4796: Fair Care Act of 2020
  • S 116-1895: Lower Health Care Costs Act
  • HR 116-8527: Fair Care Act of 2020
Congressional oversightDrug safety, medical device, and laboratory regulationPrescription drugs

MODERN Labeling Act of 2020

USA116th CongressHR-5668| House 
| Updated: 11/18/2020
Making Objective Drug Evidence Revisions for New Labeling Act of 2020 or the MODERN Labeling Act of 2020 This bill authorizes the Food and Drug Administration (FDA) to require updates to outdated labels for certain generic drugs if the updates will provide a public health benefit. Generally, the FDA may use this authority to update the label of a generic version of a brand-name drug that has been withdrawn from the market for reasons other than safety or effectiveness.

Bill Text Versions

View Text
4 versions available

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline
Jan 24, 2020
Introduced in House
Jan 24, 2020
Referred to the House Committee on Energy and Commerce.
Jan 25, 2020
Referred to the Subcommittee on Health.
Mar 11, 2020
Ordered to be Reported (Amended) by Voice Vote.
Mar 11, 2020
Subcommittee Consideration and Mark-up Session Held.
Jul 15, 2020
Ordered to be Reported (Amended) by Voice Vote.
Jul 15, 2020
Committee Consideration and Mark-up Session Held.
Nov 16, 2020
Placed on the Union Calendar, Calendar No. 471.
Nov 16, 2020
Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 116-573.
Nov 17, 2020
Mr. Pallone moved to suspend the rules and pass the bill, as amended.
Nov 17, 2020
Considered under suspension of the rules. (consideration: CR H5805-5807)
Nov 17, 2020
DEBATE - The House proceeded with forty minutes of debate on H.R. 5668.
Nov 17, 2020
Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.(text: CR H5805-5806)
Nov 17, 2020
On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H5805-5806)
Nov 17, 2020
Motion to reconsider laid on the table Agreed to without objection.
Nov 18, 2020
Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
  • January 24, 2020
    Introduced in House


  • January 24, 2020
    Referred to the House Committee on Energy and Commerce.


  • January 25, 2020
    Referred to the Subcommittee on Health.


  • March 11, 2020
    Ordered to be Reported (Amended) by Voice Vote.


  • March 11, 2020
    Subcommittee Consideration and Mark-up Session Held.


  • July 15, 2020
    Ordered to be Reported (Amended) by Voice Vote.


  • July 15, 2020
    Committee Consideration and Mark-up Session Held.


  • November 16, 2020
    Placed on the Union Calendar, Calendar No. 471.


  • November 16, 2020
    Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 116-573.


  • November 17, 2020
    Mr. Pallone moved to suspend the rules and pass the bill, as amended.


  • November 17, 2020
    Considered under suspension of the rules. (consideration: CR H5805-5807)


  • November 17, 2020
    DEBATE - The House proceeded with forty minutes of debate on H.R. 5668.


  • November 17, 2020
    Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.(text: CR H5805-5806)


  • November 17, 2020
    On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H5805-5806)


  • November 17, 2020
    Motion to reconsider laid on the table Agreed to without objection.


  • November 18, 2020
    Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Doris O. Matsui

Doris O. Matsui

Democratic Representative

California

Cosponsors (2)
Brett Guthrie (Republican)Van Taylor (Republican)

Health, Education, Labor, and Pensions Committee, Health Subcommittee, Energy and Commerce Committee

Health

Related Bills

  • S 116-1897: A bill to establish a process for updating the labeling of certain drugs with outdated labeling.
  • S 116-4796: Fair Care Act of 2020
  • S 116-1895: Lower Health Care Costs Act
  • HR 116-8527: Fair Care Act of 2020
  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted
Congressional oversightDrug safety, medical device, and laboratory regulationPrescription drugs